

#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency **Licensed:** The patent has been licensed to an entity, whether

earning royalties or not



Section 1. Identifying Inform	ation	
1. Given Name (First Name) Olga	2. Surname (Last Name) Pankova	3. Date 26-April-2020
4. Are you the corresponding author?	Yes ✓ No	Corresponding Author's Name Dr. Denisov
5. Manuscript Title Neoadjuvant chemotherapy combined small cell lung cancer (NSCLC) patients	with intraoperative radiot	therapy is effective to prevent recurrence in high-risk non-
6. Manuscript Identifying Number (if you kn TLCR-19-719	ow it)	
Section 2. The Work Under Co	onsideration for Public	cation
any aspect of the submitted work (including statistical analysis, etc.)?	but not limited to grants, da	n a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation,
Are there any relevant conflicts of intere		ve more than one entity press the "ADD" button to add a row.
Excess rows can be removed by pressing	-	vernore than one entity press the ADD button to add a row.
Name of Institution/Company	Grant	n-Financial Other? Comments
Russian Foundation for Basic Research	<b>✓</b>	Nº 17-29-06002 (sampling)
Section 3. Relevant financial	activities outside the s	submitted work.
of compensation) with entities as descri	bed in the instructions. Us port relationships that wer	nether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.
Section 4. Intellectual Proper	ty Patents & Copyric	ghts
Do you have any patents, whether plans If yes, please fill out the appropriate info Excess rows can be removed by pressing	ormation below. If you hav	roadly relevant to the work?  Yes  No



Patent?	Pending?	Issued?	Licensed?	Royalties?	Licensee?	Comments
J Patent 2538642		<b>/</b>				A method for prognosis of the development of squamous metaplasia in the bronchial epithelium
J Patent 2489718		<b>✓</b>				A method for prognosis of distant recurrence in NSCLC patients
Patent 2498305		<b>✓</b>				A method for prognosis of locoregional recurrence in NSCLC patients
Patent 2293323		<b>✓</b>				A method for prognosis of severity of bronchial dysplasia
•	activities tha ou wrote in th	at readers ne submit	could perce ted work?			hat give the appearance of
Are there other relationships or potentially influencing, what you	activities that ou wrote in the nips/conditio	nt readers ne submit ns/circun	could perce ted work? nstances are	e present (ex	plain below):	
Are there other relationships or potentially influencing, what you are always as a section of the control of th	activities that ou wrote in the nips/condition ditions/circur otance, journ outhors to dis	nt readers ne submit ns/circun nstances als will as	could perce ted work? nstances are that present	e present (ex t a potential o confirm and	plain below): conflict of inter d, if necessary, u	est ipdate their disclosure stateme
Are there other relationships or potentially influencing, what you are the following relationships or the following relation	activities that ou wrote in the nips/condition ditions/circurent otance, journ outhors to dis	nt readers ne submit ns/circun nstances als will as close furt	could perce ted work? Instances are that present k authors to ther informa	e present (ex t a potential o confirm and ation about r	plain below): conflict of inter d, if necessary, u eported relation	est Ipdate their disclosure stateme nships.
Are there other relationships or potentially influencing, what you are always as a section of the control of th	activities that ou wrote in the nips/condition ditions/circurent otance, journ outhors to dis	nt readers ne submit ns/circun nstances als will as close furt	could perce ted work? Instances are that present k authors to ther informa	e present (ex t a potential o confirm and ation about r	plain below): conflict of inter d, if necessary, u eported relation	est Ipdate their disclosure stateme nships.



#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

Rodionov

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

1

administrative support, etc.



Section 1.	Identifying Inform	nation	
1. Given Name (Fi Evgeny	rst Name)	2. Surname (Last Name) Rodionov	3. Date 26-April-2020
4. Are you the cor	responding author?	☐ Yes ✓ No	Corresponding Author's Name Dr. Denisov
		with intraoperative radiot	cherapy is effective to prevent recurrence in high-risk non-
6. Manuscript Ide TLCR-19-719	ntifying Number (if you kr	now it)	
	ı		
Section 2.	The Work Under C	onsideration for Public	cation
any aspect of the s statistical analysis,	submitted work (including	but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation,
Section 3.	Relevant financial	activities outside the s	submitted work.
of compensation clicking the "Add	n) with entities as descri	ibed in the instructions. Us port relationships that we	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.
Section 4.	Intellectual Proper	rty Patents & Copyrig	ahts
Do you have any			roadly relevant to the work? Yes V No

Rodionov 2



Section 5.	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follo	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Dr. Rodionov ha	s nothing to disclose.

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Rodionov 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

Miller 1



Section 1.	Identifying Inf	ormation					
1. Given Name (Fii Sergey	, ,		2. Surname (Last Name)  Miller  3. Date 26-April-2020				
4. Are you the cor	responding author?	Yes	<b>√</b> No	Correspon Dr. Deniso	ding Author's Nam	e	
5. Manuscript Title Neoadjuvant chemotherapy combined with intraoperative radiotherapy is effective to prevent recurrence in high-risk non-small cell lung cancer (NSCLC) patients							
6. Manuscript Ider TLCR-19-719	ntifying Number (if yo	ou know it)					
				_			
Section 2.	The Work Unde	r Consideratio	n for Publi	cation			
	ubmitted work (inclu					mercial, private foundation, et gn, manuscript preparation,	tc.) for
<del>-</del>	evant conflicts of ir	iterest? Yes	s ✓ No				
Section 3.	Relevant finance	cial activities o	utside the s	submitted	work.		
of compensation	) with entities as de	escribed in the in	structions. Us	se one line f	or each entity; ad	tionships (regardless of amo ld as many lines as you need onths prior to publication.	d by
_	evant conflicts of ir		. —	•	J		
Section 4.	Intellectual Pro	perty Patent	ts & Copyri	ghts			
If yes, please fill o	patents, whether pout the appropriate per removed by pre	information belo	ow. If you hav	-		✓ Yes No s the "ADD" button to add a	ı row.
Paten	t? Pe	nding? Issued	Licensed?	Royalties?	Licensee?	Comments	
RU Patent 2348357						A method for marking target in intraoperative radiation therapy	

Miller 2



Patent?	Pending?	Issued?	Licensed?	Royalties?	Licensee?	Comments		
RU Patent 2431450		<b>✓</b>				A method for combined treatment of locally advanced stage IIIa-IIIb NSCLC		
RU Patent 2361580		<b>√</b>				A method for treatment of patients with locally advanced NSCLC		
Costion 5								
Section 5. Relationshi	ps not cove	ered abo	ove					
Are there other relationships or potentially influencing, what yo				eive to have	influenced, or the	at give the appearance of		
Yes, the following relationsh								
✓ No other relationships/cond	itions/circun	nstances	that presen	t a potential	conflict of intere	st		
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.								
Section 6								
Disclosure S	Section 6. Disclosure Statement							
Based on the above disclosures, below.	this form wi	ll automa	tically gene	erate a disclo	sure statement, v	which will appear in the box		
Dr. Miller reports In addition, D patent RU Patent 2361580 issue		a patent F	RU Patent 2:	348357 issue	d, a patent RU Pa	atent 2431450 issued, and a		

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Miller 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Section 1.	Identifying Info	ormation					
1. Given Name (Fi Sergey	, ,		(Last Name)			3. Date 26-April-2020	
4. Are you the cor	responding author?	Yes	<b>√</b> No	Correspon Dr. Deniso	ding Author's Nam	ne	
5. Manuscript Title Neoadjuvant chemotherapy combined with intraoperative radiotherapy is effective to prevent recurrence in high-risk non-small cell lung cancer (NSCLC) patients							
6. Manuscript Ider TLCR-19-719	ntifying Number (if yo	ou know it)					
				_			
Section 2.	The Work Unde	r Consideratio	n for Publi	cation			
	ubmitted work (inclu					nmercial, private foundation, et ign, manuscript preparation,	tc.) for
<del>-</del>	evant conflicts of ir	iterest? Yes	s ✓ No				
	ı						
Section 3.	Relevant financ	ial activities o	utside the s	submitted	work.		
of compensation	) with entities as de	escribed in the in	structions. Us	se one line f	or each entity; ad	tionships (regardless of amo ld as many lines as you need onths prior to publication.	d by
_	evant conflicts of ir		. —	·	J		
Section 4.	Intellectual Pro	perty Patent	ts & Copyri	ghts			
If yes, please fill o	patents, whether pout the appropriate one removed by pre	information belo	ow. If you hav	-		✓ Yes  No s the "ADD" button to add a	i row.
Paten	t <b>?</b> Pe	nding? Issued	Licensed?	Royalties?	Licensee?	Comments	
RU Patent 2348357						A method for marking target in intraoperative radiation therapy	



Patent?	Pending?	Issued?	Licensed?	Royalties?	Licensee?	Comments
U Patent 2538642		<b>V</b>				A method for prognosis of the development of squamous metaplasia in the bronchial epithelium
U Patent 2431450		<b>✓</b>				A method for combined treatment of locally advanced stage IIIa-IIIb NSCLC
U Patent 2361580		<b>✓</b>				A method for treatment of patients with locally advanced NSCLC
On occasion, journals may ask a	itions/circur otance, journ uthors to dis	mstances i	that presen	t a potential	conflict of intere	pdate their disclosure statements
Based on the above disclosures,		ill automa	atically gene	erate a disclo	sure statement	which will appear in the box
below.	, unis ionin w	iii automa	rically gene	rate a discio	sure statement,	which will appear in the box
Dr. Tuzikov reports In addition, patent RU Patent 2431450 issu					ssued, a patent l	RU Patent 2538642 issued, a



#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

Tashireva 1



Section 1.	Identifying Inform	nation		
1. Given Name (Fii Liubov	rst Name)	2. Surname (Last Name) Tashireva		3. Date 26-April-2020
4. Are you the cor	responding author?	Yes ✓ No	Corresponding Author's Nam Dr. Denisov	e
•		with intraoperative radio	herapy is effective to preven	t recurrence in high-risk non-
6. Manuscript Ider TLCR-19-719	ntifying Number (if you kr	now it)		
	ı			
Section 2.	The Work Under Co	onsideration for Publi	cation	
any aspect of the s statistical analysis,	ubmitted work (including	but not limited to grants, da	a third party (government, com ta monitoring board, study desi	mercial, private foundation, etc.) for ign, manuscript preparation,
Section 3.	Relevant financial	activities outside the s	submitted work.	
of compensation clicking the "Add	) with entities as descri	bed in the instructions. Use port relationships that we		tionships (regardless of amount ld as many lines as you need by onths prior to publication.
Section 4.	Intellectual Proper	ty Patents & Copyric	nhts	
Do you have any	•		oadly relevant to the work?	Yes ✓ No

Tashireva 2



Section 5.	
Section 5.	Relationships not covered above
	itionships or activities that readers could perceive to have influenced, or that give the appearance of ing, what you wrote in the submitted work?
Yes, the following	ng relationships/conditions/circumstances are present (explain below):
✓ No other relatio	onships/conditions/circumstances that present a potential conflict of interest
	uscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements als may ask authors to disclose further information about reported relationships.
Section 6. D	Pisclosure Statement
Based on the above below.	e disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Dr. Tashireva has n	othing to disclose.

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Tashireva 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Gerashchenko 1



Section 1.	Identifying Inform	nation	
1. Given Name (Fi Tatiana	rst Name)	2. Surname (Last Name) Gerashchenko	3. Date 26-April-2020
4. Are you the cor	responding author?	Yes ✓ No	Corresponding Author's Name Dr. Denisov
small cell lung ca			otherapy is effective to prevent recurrence in high-risk non-
Section 2.	The Work Under Co	onsideration for Publ	ication
any aspect of the s statistical analysis,	ubmitted work (including	g but not limited to grants, c	m a third party (government, commercial, private foundation, etc.) for data monitoring board, study design, manuscript preparation,
Section 3.	Relevant financial	activities outside the	submitted work.
of compensation clicking the "Add	ı) with entities as descri	ibed in the instructions. Uport relations we	hether you have financial relationships (regardless of amount Use one line for each entity; add as many lines as you need by ere <b>present during the 36 months prior to publication</b> .
Section 4.	Intellectual Proper	rty Patents & Copyr	ights
Do you have any	patents, whether plan	ned, pending or issued, b	proadly relevant to the work? Yes V No

Gerashchenko 2



Section 5. Polationships not severed above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Gerashchenko has nothing to disclose.

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Gerashchenko 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

Denisov 1



Section 1. Identifying Inform	nation		
1. Given Name (First Name) Evgeny	2. Surname (Last Name) Denisov		3. Date 26-April-2020
4. Are you the corresponding author?	✓ Yes No		
5. Manuscript Title Neoadjuvant chemotherapy combined small cell lung cancer (NSCLC) patients	•	otherapy is effective to	prevent recurrence in high-risk non-
6. Manuscript Identifying Number (if you k TLCR-19-719	now it)		
Section 2. The Work Under C	onsideration for Publ	ication	
Did you or your institution <b>at any time</b> receany aspect of the submitted work (includin statistical analysis, etc.)?			ent, commercial, private foundation, etc.) for udy design, manuscript preparation,
Are there any relevant conflicts of inter			
If yes, please fill out the appropriate inf Excess rows can be removed by pressir	•	ve more than one entit	ty press the "ADD" button to add a row.
Name of Institution/Company	Grant	on-Financial Support? Other?	Comments
Russian Foundation for Basic Research	<b>✓</b>		№ 17-29-06002 (sampling)
Section 3. Relevant financial	activities outside the	submitted work.	
Place a check in the appropriate boxes of compensation) with entities as described to the "Add +" box. You should re Are there any relevant conflicts of inter	ribed in the instructions. Uport relationships that we	Jse one line for each en	tity; add as many lines as you need by
Section 4. Intellectual Prope	rty Patents & Copyri	ghts	
Do you have any patents, whether plar If yes, please fill out the appropriate inf Excess rows can be removed by pressir	ormation below. If you ha	•	work? Yes No ty press the "ADD" button to add a row.

Denisov 2



Patent?	Pending?	Issued?	Licensed ?	Royalties?	Licensee?	Comments	
RU Patent 2538642		<b>✓</b>				A method for prognosis of the development of squamous metaplasia in the bronchial epithelium	
Section 5. Relationshi	ps not cove	ered abo	ove				
Are there other relationships or potentially influencing, what yo			•	eive to have	influenced, or th	nat give the appearance of	
Yes, the following relationsh  No other relationships/cond	•			•	•	est	
At the time of manuscript accep On occasion, journals may ask a							ıts.
Section 6. Disclosure S	Statement						
Based on the above disclosures, below.	this form wi	ill automa	atically gene	erate a disclo	sure statement,	which will appear in the box	
Dr. Denisov reports grants from Denisov has a patent RU Patent			for Basic Re	search, durii	ng the conduct c	of the study; In addition, Dr.	

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Denisov 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your

**koyaities:** Funds are coming in to you or your institution due to you! patent



Section 1. Identifying	g Information	
1. Given Name (First Name) Vladimir	2. Surname (Last Name) Perelmuter	3. Date 26-April-2020
4. Are you the corresponding aut	hor? Yes 🗸 No	Corresponding Author's Name Dr. Denisov
5. Manuscript Title Neoadjuvant chemotherapy c small cell lung cancer (NSCLC)		otherapy is effective to prevent recurrence in high-risk non-
6. Manuscript Identifying Numbe TLCR-19-719	r (if you know it)	
Section 2. The Work l	Jnder Consideration for Publi	ication
		n a third party (government, commercial, private foundation, etc.) for lata monitoring board, study design, manuscript preparation,
Are there any relevant conflict	s of interest? Yes V No	
Section 3. Relevant fi	nancial activities outside the	submitted work.
of compensation) with entities	as described in the instructions. U hould report relationships that we	hether you have financial relationships (regardless of amount Use one line for each entity; add as many lines as you need by ere <b>present during the 36 months prior to publication</b> .
Section 4. Intellectua	l Property Patents & Copyri	ghts
• • • • • • • • • • • • • • • • • • • •	· ·	oroadly relevant to the work?  Yes  No eve more than one entity press the "ADD" button to add a row.
Patent?	Pending? Issued? Licensed?	Royalties? Licensee? Comments
RU Patent 2538642		A method for prognosis of the development of squamous metaplasia in the bronchial epithelium



Patent?	Pending?	Issued?	Licensed?	Royalties?	Licensee?	Comments
RU Patent 2489718		<b>√</b>				A method for prognosis of distant recurrence in NSCLC patients
RU Patent 2498305		<b>✓</b>				A method for prognosis of locoregional recurrence in NSCLC patients
RU Patent 2293323		<b>✓</b>				A method for prognosis of severity of bronchial dysplasia
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?  Yes, the following relationships/conditions/circumstances are present (explain below):  No other relationships/conditions/circumstances that present a potential conflict of interest						
At the time of manuscript accep On occasion, journals may ask a						
Section 6. Disclosure S	tatement					
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.						
Dr. Perelmuter reports In addit issued, a patent RU Patent 2498						patent RU Patent 2489718



#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.